Dr. Lal Pathlabs Peer Comparison

Snapshot Summary

Dr. Lal Pathlabs Ltd. stands out as a leader in the hospital and healthcare services sector, showcasing strong profitability metrics and a solid growth trajectory compared to its peers. It is relatively undervalued based on its PEG ratio, indicating potential for appreciation. However, some companies like Aster DM Healthcare appear significantly undervalued, albeit with weaker financials.

• Dr. Lal Pathlabs exhibits strong growth (10.55% YoY) and profitability (ROE at 21.27%).
• Aster DM Healthcare is the best value pick but shows financial weakness.
• Max Healthcare is overvalued with a high PE ratio (163.58) and low profitability (ROE at 13.47%).

• Dr. Lal Pathlabs Ltd.: Strong profitability with ROE at 21.27% and solid revenue growth of 10.55% YoY.
• Global Health Ltd.: High revenue growth of 21.56% YoY and decent profitability metrics.
• Apollo Hospitals Enterprise Ltd.: Good EPS growth and solid returns on equity.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
LALPATHLAB	₹3,254.90	₹27,240.86Cr	50.97	21.27%	27.89%	0.05
APOLLOHOSP	₹7,824.50	₹1,12,510.06Cr	71.50	20.51%	21.19%	0.67
MAXHEALTH	₹1,145.90	₹1,11,466.91Cr	97.13	13.47%	16.26%	0.14
FORTIS	₹1,030.70	₹77,269.97Cr	88.97	9.77%	12.14%	0.25
NH	₹1,785.00	₹36,492.71Cr	46.46	24.27%	21.62%	0.61
ASTERDM	₹678.45	₹35,159.69Cr	110.51	9.32%	11.46%	0.19
MEDANTA	₹1,274.60	₹34,290.93Cr	64.20	15.31%	20.50%	0.10

Explore

Watchlists

Command Palette

Dr. Lal Pathlabs Peer Comparison

Snapshot Summary